Moderna agreed to a near‑term settlement that will resolve long‑running patent litigation tied to its Covid‑19 vaccine. The company will pay $950 million upfront to Arbutus Biopharma and Roivant’s Genevant, with additional contingent liabilities outlined in separate reports. The settlement closes a major liability that had shadowed one of the industry’s biggest commercial vaccines and clarifies risk for investors and partners. Court filings and industry reporting indicate the deal structure includes the upfront payment and further contingent amounts that could push total exposure higher depending on appeals and third‑party coverage. Roivant‑linked reporting framed the full package as capable of reaching as much as $2.25 billion under certain circumstances, underscoring the scale of IP risk in mRNA platform commercialization.